Cargando…
P1675: SUTIMLIMAB PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH COLD AGGLUTININ DISEASE: OPEN-LABEL EXTENSION OF THE PHASE 3 CADENZA STUDY
Autores principales: | Röth, Alexander, Broome, Catherine M, Barcellini, Wilma, Jilma, Bernd, Hill, Quentin A, Cella, David, Tvedt, Tor Henrik Anderson, Yamaguchi, Masaki, Murakhovskaya, Irina, Lee, Michelle, Shafer, Frank, Wardęcki, Marek, Jayawardene, Deepthi, Yoo, Ronnie, Msihid, Jerome, Weitz, Ilene C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430149/ http://dx.doi.org/10.1097/01.HS9.0000973572.71532.1f |
Ejemplares similares
-
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up
por: Röth, Alexander, et al.
Publicado: (2023) -
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
por: Röth, Alexander, et al.
Publicado: (2022) -
P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY
por: Röth, Alexander, et al.
Publicado: (2023) -
P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK OFF-TREATMENT PERIOD (WASHOUT) IN THE PHASE 3 CADENZA STUDY
por: Röth, Alexander, et al.
Publicado: (2023) -
P1486: SERUM BIOMARKERS AS PREDICTORS OF RESPONSE TO SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): A POST-HOC ANALYSIS OF PHASE 3 CARDINAL AND CADENZA STUDY DATA
por: Barcellini, Wilma, et al.
Publicado: (2023)